ArticleGels (Basel, Switzerland)2026
Perfusion-Limited Efficacy of Platelet-Rich Plasma in Adipose Tissue Grafts.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Autologous adipose tissue (AT) grafting is often compromised by insufficient early vascularization, leading to ischemia, fibrosis, and inconsistent long-term volume retention. Incorporating platelet-rich plasma (PRP) into AT bioinks offers a clinically accessible means to enhance vascular recruitment, but the in vivo impact of PRP dosage remains unclear. Here, we investigated how PRP concentration, uniformly integrated into a previously reported clinically relevant AT bioink, regulates vascular infiltration, tissue remodeling, and overall graft survival. High-dose PRP markedly improved graft performance, including an 8-fold increase in highly perfused regions, a 3.8-fold enhancement in adipocyte survival, a 1.67-fold reduction in fibrosis, and a 2.51-fold increase in collagen III deposition compared with PRP-free AT grafts. Histological analysis further demonstrated that PRP mitigates the adverse effects of poor perfusion, reducing regional disparities in survival and extracellular matrix (ECM) remodeling. High-dose PRP also maximized graft retention, preserving 103% of graft mass relative to 50.6% in native AT. Together, these results establish a clear in vivo dose-response relationship for PRP-enhanced AT grafts and highlight platelet concentration as a key design parameter for soft-tissue reconstruction. This work provides a translational framework for optimizing PRP-functionalized bioinks to improve clinical outcomes in reconstructive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.